• 1
    Verhamme KM, Dieleman JP, Bleumink GS et al.; Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph project. Eur Urol 2002; 42: 3238
  • 2
    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 4749
  • 3
    Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 63749
  • 4
    Hansen BL. Lower urinary tract symptoms (LUTS) and sexual function in both sexes. Eur Urol 2004; 46: 22934
  • 5
    AUA Practice Guidelines Committee. AUA Guideline on Management of Benign Prostatic Hyperplasia; 2003. Chapter 3: Results of the Treatment Outcomes Analyses. Linthincum: American Urological Association, 2003
  • 6
    Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 2003; 62 (Suppl. 1): 2433
  • 7
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; On behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 4344
  • 8
    AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 53047
  • 9
    Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a shortterm prospective randomized trial. Urology 2008; 71: 24751
  • 10
    Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 25964
  • 11
    Kuo HC. Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 6704
  • 12
    Kuo HC, Liu HT. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009; 43: 20611
  • 13
    Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009; 73: 904
  • 14
    Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor B. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostate. Urology 2005; 66: 7759
  • 15
    Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006; 98: 10337
  • 16
    Silva J, Silva C, Saraiva L et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008; 53: 1539
  • 17
    Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is Botulinum Neurotoxin Type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 2008; 54: 76577
  • 18
    Silva J, Pinto R, Carvalho T et al. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 2009; 9: 9
  • 19
    Cruz F, Dinis P. Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn 2007; 26 (Suppl. 6): 9207
  • 20
    Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13 (Suppl. 4): 19
  • 21
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 82230
  • 22
    Silva J, Pinto R, Carvalho T et al. Mechanisms of prostate atrophy after Glandular Botulinum Neurotoxin Type A injection: an experimental study in the rat. Eur Urol 2009; 56: 13441
  • 23
    Lin ATL, Yang AH, Chen K-K. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52: 5829
  • 24
    Crawford ED, Donnell R, Hirst K et al. 12-week results of a phase II trial of 100 and 300 units Botulinum Toxin Type A (BONT-A) for the management of benign prostatic hyperplasia (BPH). J Urol 2009; 181 (Suppl. 1): 64950
  • 25
    Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet 2003; 361: 602
  • 26
    Kobayashi K, Masumori N, Hisasue S et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha 1A-blocker in normal volunteers. J Sex Med 2008; 5: 218590
  • 27
    Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009; 55: 3848
  • 28
    Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med 2009; 6: 2299304
  • 29
    Grimm RH, Grandits GA, Prineas RJ et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29: 814